Other substances

mAb 2-15

An anti-RBD (SARS-CoV-2 Spike) human monoclonal antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

mAb 2-15 is a human monoclonal antibody that was selected due to its affinity for SARS-CoV-2 Spike protein RBD. It was identified in a screening of memory B cells of COVID-19 convalescent patients (Liu et al., 2020). The antibody’s tertiary structure and interaction with Spike RBD has been described by Rapp et al. (2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Spike protein Animal model In vitro Antibody 		in vitro binding assay; Vero cells; golden Syrian hamsters; SARS-CoV-2 strain USA-WA1/2020 42.78

The antibody neutralized SARS-CoV-2 pseudotyped and live virus with IC50s of 0.005 and 0.0007 μg/ml, respectively. When prophylactically administered to golden Syrian hamsters at 1.5 mg/kg, significant reduction of viral RNA copy numbers was observed after a viral challenge

 Jul/22/2020
Export (.csv)